Get the Stockscreener App
0.349
0.66%
0.0023
Spruce Biosciences Inc stock is traded at $0.349, with a volume of 143.69K.
It is up +0.66% in the last 24 hours and down -14.96% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
See More
Previous Close:
$0.3467
Open:
$0.3425
24h Volume:
143.69K
Relative Volume:
0.26
Market Cap:
$14.41M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-0.3713
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
-2.84%
1M Performance:
-14.96%
6M Performance:
-23.75%
1Y Performance:
-92.96%
1-Day Range:
$0.335
$0.358
1-Week Range:
$0.335
$0.3654
52-Week Range:
$0.335
$5.25
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.349 | 14.41M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline By Investing.com - Investing.com South Africa
SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline - Investing.com
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Spruce Biosciences (SPRB) to Release Quarterly Earnings on Wednesday - Defense World
Harbour Biomed newco HBM Alpha pens $395M hyperplasia drug deal - BioWorld Online
SPRB stock touches 52-week low at $0.34 amid sharp annual decline - Investing.com
Archer-Daniels-Midland Company (NYSE:ADM) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update - Defense World
Short Interest in Kingsoft Co. Limited (OTCMKTS:KSFTF) Increases By 79.4% - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Short Interest Up 81.4% in February - Defense World
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates - MSN
NeoGenomics (NEO) Tops Q4 Earnings Estimates - Yahoo Finance
The Prothena Corporation plc (PRTA) had a good session last reading, didn’t it? - US Post News
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus Target Price from Analysts - Defense World
Element Solutions Inc (NYSE:ESI) Receives $30.14 Consensus Price Target from Analysts - Defense World
Alamos Gold Inc. (TSE:AGI) Receives C$28.78 Average Target Price from Brokerages - Defense World
Spruce Biosciences Inc [SPRB] Investment Appeal on the Rise - Knox Daily
Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
Why you might not want to use AI to spruce up your job application - Yahoo
Spruce Biosciences Inc (SPRB) Stock Price and Analyst Predictions - The News Heater
Spruce Biosciences Inc (NASDAQ:SPRB) stock: You might be surprised - US Post News
Examining OppFi Inc (OPFI) stock is warranted - US Post News
(PDF) Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials - ResearchGate
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus Target Price from Brokerages - Defense World
After A 1.47% Jump In The Last Week, Does Amprius Technologies Inc (NYSE: AMPX) Still Make Sense To Buy? - Marketing Sentinel
CMS’ price negotiations take two: Ozempic, Xtandi among 15 drugs chosen - BioWorld Online
Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law
Spruce Biosciences, Inc. (NASDAQ:SPRB) Sees Large Decrease in Short Interest - Defense World
Mapletree Industrial Trust (OTCMKTS:MAPIF) Short Interest Down 50.6% in December - Defense World
SPRB stock touches 52-week low at $0.36 amid market challenges - Investing.com Australia
SPRB stock touches 52-week low at $0.36 amid market challenges By Investing.com - Investing.com South Africa
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Congenital Adrenal Hyperplasia Pipeline Analysis 2024: FDA Approvals and Emerging Therapies | Becton, Dickinson and Company, Cook Medical, Cooper Surgical, Smiths Medical, Rocket Medical, CENTOGENE - Barchart
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Spruce Biosciences Appoints Interim Chief Medical Officer - MSN
Enovix Appoints First Chief Accounting Officer as Global Operations Expand Ahead of 2025 Growth - StockTitan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus PT from Analysts - Defense World
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):